Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811459 | 0.95 | TSHR (0.56) | TSHRHSD17B10POLBALDH1A1TDP1 | |
| Sulfuric Acid SCHEMBL1819503 | 0.94 | TSHR (0.56) | TSHRHSD17B10POLBALDH1A1TDP1 | |
| SCHEMBL26393724 | 0.94 | FAAH (0.55) | TSHRHSD17B10POLBALDH1A1TDP1 | |
| SCHEMBL9633498 | 0.94 | FAAH (0.55) | TSHRHSD17B10POLBALDH1A1TDP1 | |
| SCHEMBL28207523 | 0.93 | TSHR (0.55) | TSHRHSD17B10POLBALDH1A1TDP1 | |
| SCHEMBL7158304 | 0.92 | ALDH1A1 (0.63) | HSD17B10ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL85431 | 0.90 | TSHR (0.60) | TSHRHSD17B10POLBALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL5843426 | 0.89 | TSHR (0.62) | TSHRHSD17B10POLBALDH1A1TDP1 | |
| SCHEMBL21999365 | 0.87 | ALDH1A1 (0.60) | HSD17B10ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL21999366 | 0.87 | ALDH1A1 (0.60) | HSD17B10ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192470-A1 | METHOD OF TREATING GLIOBLASTOMA OR OTHER CANCERS EXPRESSING P75 NEUROTROPHIN RECEPTOR | THE UNIVERSITY OF NEWCASTLE (AU) | 2024-09-26 | — | — | WO | disclosed |
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2022-05-26 | — | — | US | disclosed |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-2498782-B1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX INC (US) | 2019-01-09 | — | — | EP | disclosed |
| CN-108383804-A | The crystal form of neurotrophin simulated compound and its salt | 特罗菲克斯制药股份有限公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-104761515-B | The crystal formation of neurotrophin simulated compound and its salt | 特罗菲克斯制药股份有限公司 | 2018-03-09 | — | — | CN | disclosed |
| WO-2018039641-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | PHARMATROPHIX, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-9884833-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | PHARMATROPHIX, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2017176040-A1 | HETEROCYCLIC COMPOUND DECOMPOSING RAS AND USES THEREOF | 연세대학교 산학협력단 | 2017-10-12 | — | — | WO | disclosed |
| WO-2017044849-A1 | CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-8933077-B2 | Glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2012167869-A1 | AMINO LIPIDS, THEIR SYNTHESIS AND USES THEREOF | Karlsruher Institut für Technologie (DE) | 2012-12-13 | — | — | WO | disclosed |
| EP-2498782-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | Pharmatrophix Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2403839-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | The University of North Carolina At Chapel Hill (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011066544-A2 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
| WO-2010102212-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 971/4885HSD17B10 4564/4885POLB 4271/4885 |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | TSHR 3628/4885HSD17B10 3831/4885POLB 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.